The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study.

MJ, Millward; C, House; D, Bowtell; L, Webster; IN, Olver; M, Gore; M, Copeman; K, Lynch; A, Yap; Y, Wang; PS, Cohen; J, Zalcberg

doi:10.1038/sj.bjc.6603331

Public

The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study.

Shared by NobleBlocks on Sep 12, 2006 • 12:00 AM UTC

Authors:

Millward MJ

House C

Bowtell D

Abstract

Midostaurin (PKC412A), N-benzoyl-staurosporine, potently inhibits protein kinase C alpha (PKCalpha), VEGFR2, KIT, PDGFR and FLT3 tyrosine kinases. In mice, midostaurin slows growth and delays lung metastasis of melanoma cell lines. We aimed to test midostaurin's safety, efficacy and biologic activit...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!